Metagenomi Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $94.4M | $109.2M | $94.4M |
| SG&A Expense | $26.8M | $32.0M | $28.8M |
| Operating Income | $-96.0M | $-88.9M | $-78.5M |
| Operating Margin | -380.9% | -170.0% | -175.4% |
| Interest Expense | — | — | — |
| Pretax Income | $-87.9M | $-83.6M | $-60.2M |
| Income Tax Expense | $-58.0K | $-5.5M | $8.0M |
| Net Income | $-87.9M | $-78.1M | $-68.3M |
| Net Margin | -348.5% | -149.3% | -152.5% |
| EPS (Basic) | $-2.36 | $-2.36 | $-2.01 |
| EPS (Diluted) | $-2.36 | $-2.36 | $-2.01 |
| Shares Outstanding (Basic) | 37.3M | 33.0M | 34.0M |
| Shares Outstanding (Diluted) | 37.3M | 33.0M | 34.0M |
| Dividends Per Share | — | — | — |